Analysts Target Healthy Drug Stocks

Pharmaceutical stocks were winners today on the earnings front, and CNBC guests say they can be winners on the portfolio front as well.

Robert Hazlett, pharmaceuticals analyst at BMO Capital Markets, says the sector is a good bet for the very near term. (Catch his full comments in the video)

“These companies have reasonably good fundamentals, you don’t have to take out a new mortgage to fill your prescription, they are big, liquid companies…they have robust dividends and then last, but not least, the political will for change is low in terms of these companies.”

Hazlett’s favorite stocks in the sector are Schering-Plough , which he says has no meaningful patent expirations for four to five years, and Bristol-Myers


Bruce Nudell, medical supply analyst at UBS, likes Baxter International, Abbott Labs and Zimmer Holdings .

More from

  • Caterpillar Profit Disappoints, Keeps Outlook
  • Buffett's Pro-Stock Stance Backed By Big Short-Seller
  • Cramer to CEOs: Just Say Yes to Takeovers
  • _________________________